Fosamax and Osteonecrosis of the Jaw: Clinical Evidence Review

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

General Health and Science Information Legacy

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and therapeutic interventions. Within this broad context, the dissemination of knowledge regarding osteoporosis management and the use of bisphosphonates like Fosamax has been a standard component of patient education. This heritage emphasizes the balance between therapeutic benefit and potential adverse effects, a principle that underpins clinical vigilance. Transitioning from this general health perspective to a more focused occupational exposure concern requires a shift in analytical lens. While the clinical setting primarily addresses patient-specific risk factors and dosing regimens, the occupational environment introduces distinct variables. Healthcare professionals, particularly those in surgical and dental specialties, may encounter patients with a history of Fosamax use who present with jaw-related complications. The concern here is not merely the pharmacological action of the drug, but the practical implications of managing such cases in a clinical workflow. This pivot reframes the discussion from population-level health education to a targeted, practice-based consideration of exposure history and its relevance to procedural outcomes. The bridge concept thus moves from broad awareness to specific, actionable risk assessment in professional practice.

Bridge to Clinical Risk Assessment

The transition from general health education to focused clinical risk assessment is essential for healthcare providers managing patients with Fosamax exposure. While the general public benefits from awareness of osteoporosis treatments, clinicians must integrate specific knowledge about adverse effects like osteonecrosis of the jaw (ONJ) into their practice. This section bridges the gap by emphasizing the importance of taking a thorough medication history, recognizing risk factors, and understanding the mechanistic basis for ONJ. The following sections delve into the pharmacological evidence, clinical presentation, and management strategies, providing a comprehensive resource for informed decision-making.

Pharmacology and Mechanism of Fosamax

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use, however, has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). This condition involves necrotic, exposed bone in the maxillofacial region that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The pharmacology of Fosamax involves inhibition of osteoclast-mediated bone resorption, which reduces bone turnover. While this effect is beneficial for increasing bone mass and reducing fracture risk in osteoporosis, it can also impair the normal remodeling and repair processes in the jawbone. The mechanistic pathways linking Fosamax to ONJ are thought to involve suppression of bone turnover, leading to accumulation of microdamage and reduced ability to heal after dental procedures. Additionally, bisphosphonates may have anti-angiogenic effects, further compromising blood supply to the jawbone.

Clinical Presentation and Diagnosis of ONJ

The clinical presentation of ONJ typically involves exposed, necrotic bone in the jaw that persists for more than eight weeks in the absence of prior radiation therapy. Diagnosis is based on clinical examination and imaging, with a focus on identifying areas of exposed bone, fistulae, or infection. The condition can be painful and may lead to significant morbidity, including difficulty eating, speaking, and maintaining oral hygiene. The multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research underscores the unique susceptibility of the jawbone to bisphosphonate-induced damage, likely due to its high bone turnover rate and frequent exposure to microtrauma from dental procedures.

Risk Factors and Causation

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under Warnings and Precautions. This section notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that it is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal timing of discontinuation or the duration of risk after stopping the drug. The time to onset of symptoms varied from one day to several months after starting the drug, and most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset of patients had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), suggesting that the background incidence of ONJ in the general population may be low, but the drug increases risk in susceptible individuals. Causation-related considerations for affected patients are complex. While ONJ is a known adverse effect of bisphosphonates, establishing a direct causal link in an individual patient requires careful evaluation of temporal relationship, exclusion of other causes, and consideration of risk factors.

Management and Prevention Strategies

For patients who develop ONJ, management typically involves conservative measures such as oral rinses, antibiotics, and limited debridement, with avoidance of extensive surgery. The label advises to discontinue use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, Fosamax is an effective medication for osteoporosis and other bone conditions, but its use carries a risk of osteonecrosis of the jaw, particularly in patients with additional risk factors such as dental procedures, cancer, or concomitant therapies. The prescribing information includes warnings about this risk, but the variability in onset and the lack of definitive preventive strategies highlight the need for careful patient selection and monitoring. Patients should be informed about the signs and symptoms of ONJ and advised to maintain good oral hygiene and undergo dental evaluations before starting bisphosphonate therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that can cause osteonecrosis of the jaw (ONJ), a condition involving necrotic bone in the jaw. The risk is increased with dental procedures, cancer, and other factors. The prescribing information includes warnings about ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease. Duration of bisphosphonate use may also increase risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is ONJ diagnosed and managed?

Diagnosis is based on clinical exam and imaging showing exposed bone persisting >8 weeks without radiation. Management includes conservative measures like oral rinses, antibiotics, and limited debridement. Discontinuation of Fosamax may be advised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.